---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010014"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T17:33:27.637320+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ensysce reports FY2023 net loss of $10.6M; cash $1.1M; FDA Breakthrough for PF614-MPAR

## Summary
- Net loss Q4 2023 $3.5M vs $5.5M; full year $10.6M vs $25.1M (prior year).
- Cash $1.1M at Dec 31, 2023; raised $6.8M from warrant exercises in Jan & Feb 2024.
- R&D expenses fell to $2.2M (Q4) and $7.6M (FY) from $6.4M and $19.8M.
- FDA granted Breakthrough Therapy designation for PF614-MPAR in January 2024.
- Phase 3 enrollment for PF614 expected H2 2024 after positive End-of-Phase 2 meeting.

## SEC filing metadata
- accession: 0001493152-24-010014
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/0001493152-24-010014-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010014
- JSON: https://secwatch.observer/filing/0001493152-24-010014.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010014.txt

## Key facts
- Earnings Releases
  Ensysce Biosciences, Inc. reported financial results for the fourth quarter and full year of 2023.
  - Period: the fourth quarter and full year of 2023
  - Result: reported results
  source text: On March 15, 2024, Ensysce Biosciences, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter and year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315224010014/0001493152-24-010014-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.